Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases
- PMID: 24594678
- PMCID: PMC4086777
- DOI: 10.1097/NMD.0000000000000113
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases
Abstract
A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases. Treatment included drug-free psychotherapy sessions supplemented by two LSD-assisted psychotherapy sessions 2 to 3 weeks apart. The participants received either 200 μg of LSD (n = 8) or 20 μg of LSD with an open-label crossover to 200 μg of LSD after the initial blinded treatment was unmasked (n = 4). At the 2-month follow-up, positive trends were found via the State-Trait Anxiety Inventory (STAI) in reductions in trait anxiety (p = 0.033) with an effect size of 1.1, and state anxiety was significantly reduced (p = 0.021) with an effect size of 1.2, with no acute or chronic adverse effects persisting beyond 1 day after treatment or treatment-related serious adverse events. STAI reductions were sustained for 12 months. These results indicate that when administered safely in a methodologically rigorous medically supervised psychotherapeutic setting, LSD can reduce anxiety, suggesting that larger controlled studies are warranted.
Trial registration: ClinicalTrials.gov NCT00920387.
Figures
Similar articles
-
LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up.Br J Psychiatry. 2024 Sep;225(3):362-370. doi: 10.1192/bjp.2024.99. Br J Psychiatry. 2024. PMID: 39078038 Free PMC article. Clinical Trial.
-
LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects.J Psychopharmacol. 2015 Jan;29(1):57-68. doi: 10.1177/0269881114555249. Epub 2014 Nov 11. J Psychopharmacol. 2015. PMID: 25389218 Clinical Trial.
-
Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study.Biol Psychiatry. 2023 Feb 1;93(3):215-223. doi: 10.1016/j.biopsych.2022.08.025. Epub 2022 Sep 5. Biol Psychiatry. 2023. PMID: 36266118 Clinical Trial.
-
Lysergic Acid Diethylamide (LSD) for the Treatment of Anxiety Disorders: Preclinical and Clinical Evidence.CNS Drugs. 2023 Sep;37(9):733-754. doi: 10.1007/s40263-023-01008-5. Epub 2023 Aug 21. CNS Drugs. 2023. PMID: 37603260 Review.
-
Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD).ACS Chem Neurosci. 2018 Oct 17;9(10):2331-2343. doi: 10.1021/acschemneuro.8b00043. Epub 2018 Mar 1. ACS Chem Neurosci. 2018. PMID: 29461039 Review.
Cited by
-
The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review.CNS Drugs. 2023 Dec;37(12):1027-1063. doi: 10.1007/s40263-023-01044-1. Epub 2023 Nov 24. CNS Drugs. 2023. PMID: 37999867 Free PMC article.
-
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science.J Psychopharmacol. 2022 Mar;36(3):258-272. doi: 10.1177/02698811211069100. Epub 2022 Feb 2. J Psychopharmacol. 2022. PMID: 35107059 Free PMC article. Review.
-
Transcriptomic Analysis of Glycosylation and Neuroregulatory Pathways in Rodent Models in Response to Psychedelic Molecules.Int J Mol Sci. 2023 Jan 7;24(2):1200. doi: 10.3390/ijms24021200. Int J Mol Sci. 2023. PMID: 36674723 Free PMC article.
-
LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality.Neuropsychopharmacology. 2016 Oct;41(11):2638-46. doi: 10.1038/npp.2016.82. Epub 2016 Jun 1. Neuropsychopharmacology. 2016. PMID: 27249781 Free PMC article. Clinical Trial.
-
Towards an understanding of psychedelic-induced neuroplasticity.Neuropsychopharmacology. 2023 Jan;48(1):104-112. doi: 10.1038/s41386-022-01389-z. Epub 2022 Sep 19. Neuropsychopharmacology. 2023. PMID: 36123427 Free PMC article. Review.
References
-
- Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Fletchner H, Fleischman SB, de Haes JC. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 85: 365– 376 - PubMed
-
- Abramson H. (Ed) (1967). The use of LSD in psychotherapy and alcoholism. New York: Bobbs-Merrill
-
- Bonson KR, Buckholtz JW, Murphy DL. (1996). Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology. 14: 425– 436 - PubMed
-
- Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, Tyacke RJ, Leech R, Malizia AL, Murphy K, Hobden P, Evans J, Feilding A, Wise RG, Nutt DJ. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 109: 2138– 2143 - PMC - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
